Combangio, Inc, 1490 OBrien Dr, Ste C, Menlo Park, CA 94025, US

CohBar, Inc. is a clinical stage biotechnology company based in Menlo Park, CA, that harnesses the power of mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics for chronic and age-related diseases. Their approach is rooted in the symbiotic relationship between mitochondria and human cells, allowing them to tap into the evolutionary pressure that has shaped these peptides. With a focus on addressing unmet medical needs, CohBar aims to target conditions such as nonalcoholic steatohepatitis (NASH), obesity, and idiopathic pulmonary fibrosis (IPF). Through their technology platform, CohBar has discovered unique peptide families with distinct mechanisms of action. One of their promising candidates, CB4211, has shown positive results in a Phase 1a/1b study for NASH and obesity, demonstrating its potential as a first-in-class therapeutic. Additionally, their CB5138 Analogs have exhibited efficacy in preclinical models of IPF and other fibrotic diseases. By leveraging the therapeutic potential of mitochondrial-derived peptides, CohBar is dedicated to changing lives and addressing significant medical challenges.Generated from the website

Hexagon Bio, Inc

Virobay

Omt Therapeutics